Do Patient Characteristics Explain the Differences in Outcome between Medically Treated Patients in SAMMPRIS and WASID?

Seemant Chaturvedi, Tanya N. Turan, Michael J. Lynn, Colin P. Derdeyn, David Fiorella, L. Scott Janis, Marc I. Chimowitz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and Purpose - The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) medical group had a much lower primary end point rate than predicted from the preceding Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial. This result has been attributed to the aggressive medical therapy used in SAMMPRIS, but an alternative hypothesis is that SAMMPRIS patients were at lower risk. We undertook analyses to evaluate these competing hypotheses. Methods - Using proportional hazards regression, we compared the SAMMPRIS primary end point between SAMMPRIS medical patients and WASID patients meeting the same qualifying criteria adjusted for confounding baseline characteristics. Results - The unadjusted comparison of the SAMMPRIS primary end point showed a significantly higher risk for WASID patients (P=0.009, logrank test) with 12 month Kaplan-Meier estimates of 21.9% in WASID and 12.6% in SAMMPRIS and hazard ratio 1.9 (95% confidence interval =1.2-3.0). The analyses identified the following confounding factors that varied between the studies and that conferred a higher risk: lack of statin use at enrollment (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.027) that was more prevalent among WASID patients (39% versus 14%, P<0.0001) and prior infarcts in the territory of the symptomatic vessel (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.023) that was more prevalent among SAMMPRIS patients (34% versus 22%, P=0.015).The hazard ratio for WASID versus SAMMPRIS adjusted for these 2 characteristics was 1.9 (95% confidence interval =1.1-3.2). Conclusions - After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.

Original languageEnglish (US)
Pages (from-to)2562-2567
Number of pages6
JournalStroke
Volume46
Issue number9
DOIs
StatePublished - Sep 28 2015

Fingerprint

Warfarin
Aspirin
Pathologic Constriction
Stroke
Confidence Intervals
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kaplan-Meier Estimate
Clinical Trials

Keywords

  • atherosclerosis
  • dyslipidemia
  • intracranial atherosclerosis
  • stroke
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Do Patient Characteristics Explain the Differences in Outcome between Medically Treated Patients in SAMMPRIS and WASID? / Chaturvedi, Seemant; Turan, Tanya N.; Lynn, Michael J.; Derdeyn, Colin P.; Fiorella, David; Janis, L. Scott; Chimowitz, Marc I.

In: Stroke, Vol. 46, No. 9, 28.09.2015, p. 2562-2567.

Research output: Contribution to journalArticle

Chaturvedi, Seemant ; Turan, Tanya N. ; Lynn, Michael J. ; Derdeyn, Colin P. ; Fiorella, David ; Janis, L. Scott ; Chimowitz, Marc I. / Do Patient Characteristics Explain the Differences in Outcome between Medically Treated Patients in SAMMPRIS and WASID?. In: Stroke. 2015 ; Vol. 46, No. 9. pp. 2562-2567.
@article{82d9376e44f84d92b3609cfaf6ced633,
title = "Do Patient Characteristics Explain the Differences in Outcome between Medically Treated Patients in SAMMPRIS and WASID?",
abstract = "Background and Purpose - The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) medical group had a much lower primary end point rate than predicted from the preceding Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial. This result has been attributed to the aggressive medical therapy used in SAMMPRIS, but an alternative hypothesis is that SAMMPRIS patients were at lower risk. We undertook analyses to evaluate these competing hypotheses. Methods - Using proportional hazards regression, we compared the SAMMPRIS primary end point between SAMMPRIS medical patients and WASID patients meeting the same qualifying criteria adjusted for confounding baseline characteristics. Results - The unadjusted comparison of the SAMMPRIS primary end point showed a significantly higher risk for WASID patients (P=0.009, logrank test) with 12 month Kaplan-Meier estimates of 21.9{\%} in WASID and 12.6{\%} in SAMMPRIS and hazard ratio 1.9 (95{\%} confidence interval =1.2-3.0). The analyses identified the following confounding factors that varied between the studies and that conferred a higher risk: lack of statin use at enrollment (hazard ratio =1.8, 95{\%} confidence interval =1.1-2.9, P=0.027) that was more prevalent among WASID patients (39{\%} versus 14{\%}, P<0.0001) and prior infarcts in the territory of the symptomatic vessel (hazard ratio =1.8, 95{\%} confidence interval =1.1-2.9, P=0.023) that was more prevalent among SAMMPRIS patients (34{\%} versus 22{\%}, P=0.015).The hazard ratio for WASID versus SAMMPRIS adjusted for these 2 characteristics was 1.9 (95{\%} confidence interval =1.1-3.2). Conclusions - After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.",
keywords = "atherosclerosis, dyslipidemia, intracranial atherosclerosis, stroke, warfarin",
author = "Seemant Chaturvedi and Turan, {Tanya N.} and Lynn, {Michael J.} and Derdeyn, {Colin P.} and David Fiorella and Janis, {L. Scott} and Chimowitz, {Marc I.}",
year = "2015",
month = "9",
day = "28",
doi = "10.1161/STROKEAHA.115.009656",
language = "English (US)",
volume = "46",
pages = "2562--2567",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Do Patient Characteristics Explain the Differences in Outcome between Medically Treated Patients in SAMMPRIS and WASID?

AU - Chaturvedi, Seemant

AU - Turan, Tanya N.

AU - Lynn, Michael J.

AU - Derdeyn, Colin P.

AU - Fiorella, David

AU - Janis, L. Scott

AU - Chimowitz, Marc I.

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Background and Purpose - The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) medical group had a much lower primary end point rate than predicted from the preceding Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial. This result has been attributed to the aggressive medical therapy used in SAMMPRIS, but an alternative hypothesis is that SAMMPRIS patients were at lower risk. We undertook analyses to evaluate these competing hypotheses. Methods - Using proportional hazards regression, we compared the SAMMPRIS primary end point between SAMMPRIS medical patients and WASID patients meeting the same qualifying criteria adjusted for confounding baseline characteristics. Results - The unadjusted comparison of the SAMMPRIS primary end point showed a significantly higher risk for WASID patients (P=0.009, logrank test) with 12 month Kaplan-Meier estimates of 21.9% in WASID and 12.6% in SAMMPRIS and hazard ratio 1.9 (95% confidence interval =1.2-3.0). The analyses identified the following confounding factors that varied between the studies and that conferred a higher risk: lack of statin use at enrollment (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.027) that was more prevalent among WASID patients (39% versus 14%, P<0.0001) and prior infarcts in the territory of the symptomatic vessel (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.023) that was more prevalent among SAMMPRIS patients (34% versus 22%, P=0.015).The hazard ratio for WASID versus SAMMPRIS adjusted for these 2 characteristics was 1.9 (95% confidence interval =1.1-3.2). Conclusions - After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.

AB - Background and Purpose - The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) medical group had a much lower primary end point rate than predicted from the preceding Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial. This result has been attributed to the aggressive medical therapy used in SAMMPRIS, but an alternative hypothesis is that SAMMPRIS patients were at lower risk. We undertook analyses to evaluate these competing hypotheses. Methods - Using proportional hazards regression, we compared the SAMMPRIS primary end point between SAMMPRIS medical patients and WASID patients meeting the same qualifying criteria adjusted for confounding baseline characteristics. Results - The unadjusted comparison of the SAMMPRIS primary end point showed a significantly higher risk for WASID patients (P=0.009, logrank test) with 12 month Kaplan-Meier estimates of 21.9% in WASID and 12.6% in SAMMPRIS and hazard ratio 1.9 (95% confidence interval =1.2-3.0). The analyses identified the following confounding factors that varied between the studies and that conferred a higher risk: lack of statin use at enrollment (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.027) that was more prevalent among WASID patients (39% versus 14%, P<0.0001) and prior infarcts in the territory of the symptomatic vessel (hazard ratio =1.8, 95% confidence interval =1.1-2.9, P=0.023) that was more prevalent among SAMMPRIS patients (34% versus 22%, P=0.015).The hazard ratio for WASID versus SAMMPRIS adjusted for these 2 characteristics was 1.9 (95% confidence interval =1.1-3.2). Conclusions - After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.

KW - atherosclerosis

KW - dyslipidemia

KW - intracranial atherosclerosis

KW - stroke

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84940382133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940382133&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.115.009656

DO - 10.1161/STROKEAHA.115.009656

M3 - Article

C2 - 26251251

AN - SCOPUS:84940382133

VL - 46

SP - 2562

EP - 2567

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -